Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met
09. Januar 2023 06:00 ET
|
Ocugen
Study met both co-primary endpoints with robust immune responses COVAXIN™ was found to be well-tolerated in vaccine-naïve individuals and in individuals previously vaccinated with mRNA vaccines in the...
Ocugen Provides Business Update & Third Quarter 2022 Financial Results
08. November 2022 07:30 ET
|
Ocugen
Conference Call and Webcast Today at 8:30 a.m. ET Initiated dosing in the third and final cohort of U.S. Phase 1/2 OCU400 gene therapy clinical trialExpanded product pipeline with OCU500—Ocugen’s...
Ocugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences
06. Oktober 2022 08:00 ET
|
Ocugen
MALVERN, Pa., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen To Host Conference Call on Friday, August 5 at 8:30 a.m. ET to Discuss Business Updates and Second Quarter 2022 Financial Results
29. Juli 2022 07:30 ET
|
Ocugen
MALVERN, Pa., July 29, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel cell and...
Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN™ (BBV152)
23. Mai 2022 06:36 ET
|
Ocugen
MALVERN, Pa., May 23, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and...
Ocugen Provides Business Update and First Quarter 2022 Financial Results
06. Mai 2022 06:33 ET
|
Ocugen
Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 1/2 clinical trial for groundbreaking modifier gene therapy for the treatment of NR2E3 and RHO-related retinitis pigmentosa is...
Ocugen, Inc. to Commercialize COVAXIN™ in Mexico, Rights Now Encompassing All of North America
18. April 2022 07:11 ET
|
Ocugen
• Ocugen responsible for commercialization of COVAXIN™ in Mexico • COVAXIN™, already authorized for emergency use in adults by health regulators in Mexico, has been submitted for Emergency Use...
Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152)
12. April 2022 08:31 ET
|
Ocugen
MALVERN, Pa., April 12, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and...
Ocugen Provides an Update on its COVAXIN™ Pediatric (2-18) Emergency Use Authorization (EUA) Request
04. März 2022 07:01 ET
|
Ocugen
MALVERN, Pa., March 04, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to...
Ocugen Provides Business Update With Fourth Quarter and Full Year 2021 Financial Results
25. Februar 2022 07:31 ET
|
Ocugen
U.S. FDA lifts clinical hold on IND application for COVAXIN™ (BBV152), clearing the pathway for Phase 2/3 clinical trial in support of a BLA submissionEngagement with U.S. FDA to advance pediatric EUA...